flora peyvandi/X
Dec 8, 2025, 07:42
Flora Peyvandi: Anti-emicizumab Antibodies and Their Relevance in Clinical Practice
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
“The development of anti-emicizumab antibodies is a rare event, particularly those with neutralizing activity. Routine monitoring should be reserved only for patients with clinical manifestations of bleeding when therapy failure is suspected.”
Title: Anti-emicizumab antibodies and their relevance in clinical practice
Authors: Carla Valsecchi, Lucia Schiavone, Sara Arcudi, Adriana Torri, Cristina Novembrino, Flora Peyvandi
Read the full article.
More posts featuring Flora Peyvandi on Hemostasis Today.
-
Jan 24, 2026, 15:54Nicolas Nesseler on How Common and Serious is Post-Op Bleeding After Heart Transplantation
-
Jan 24, 2026, 15:43Roey Tagansky on Tu Youyou and the Rediscovery That Defeated Malaria
-
Jan 24, 2026, 15:27Mavis Agnes Kisakye on Community Impact at HFU
-
Jan 24, 2026, 15:15Jo Jewell Announces Novartis Foundation and Novo Nordisk Collaboration
-
Jan 24, 2026, 15:02Todd Davenport on The Impacts of Long COVID
-
Jan 24, 2026, 14:47Seth D Ginsberg: Last Month, Something Meaningful Happened in Tokyo
-
Jan 24, 2026, 14:33Heghine Khachatryan on New Insights Into Bleeding Mechanisms in Acquired Hemophilia A
-
Jan 24, 2026, 14:21Mamta Soni Shares Highlights from CBC Chennai 2026
-
Jan 24, 2026, 13:52Larysa Mykhailova on Characterization of Allogeneic Platelet Gel